Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:INSM News 18 December 2025 - 2 January 2026

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia stock drops 8% today as put-option hedging spikes — what’s next for LQDANEW YORK, Jan 2, 2026, 14:24 ET — Regular session

Liquidia shares fell about 8% Friday, closing at $31.70 after swinging between $30.76 and $34.97 on heavy volume. Options trading showed a surge in put buying, with 15,696 contracts traded, 56% above normal. The drop outpaced biotech peers as investors watched for updates on the company’s patent dispute over Yutrepia and its next earnings report, expected March 18.
2 January 2026
···
Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open

Insmed shares closed Monday at $175.76, up 0.53%, then traded between $175.76 and $178.05 after hours. The stock joined the Nasdaq-100 effective Dec. 22, prompting index-related activity. No new company announcements appeared after the bell. Investors continued to weigh last week’s brensocatib CRSsNP trial failure.
23 December 2025
··
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed joined the Nasdaq-100 Index on December 22, 2025, boosting its stock visibility. Shares traded at $177.86, up 1.7%, after recent swings triggered by a failed Phase 2b trial for brensocatib in chronic rhinosinusitis, which led the company to end that program. Insmed also acquired INS1148, a Phase 2–ready monoclonal antibody, for $40 million upfront.
22 December 2025
·
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025)

Insmed will join the Nasdaq-100 before markets open Monday, December 22, 2025. Shares fell 11% last week after the company halted development of brensocatib in chronic rhinosinusitis without nasal polyps following a failed Phase 2b trial. The stock last traded near $174.84. Holiday trading may affect liquidity and volatility.
21 December 2025
·
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed shares closed at $174.84 Friday, rebounding 5% after a sharp drop triggered by its Phase 2b BiRCh trial failure in chronic rhinosinusitis without nasal polyps. The company discontinued development for that indication and announced the acquisition of a Phase 2–ready monoclonal antibody, INS1148, to expand its pipeline.
20 December 2025
··
Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed (INSM) Stock After Hours on Dec. 19, 2025: Friday Rebound Holds, Analyst Targets Reset, and What to Watch Before the Next Market Open

Insmed shares closed Friday, Dec. 19, 2025, at $174.84, up nearly 5%, after a volatile week triggered by a failed Phase 2b trial for brensocatib in CRSsNP. The company said it would discontinue that program. Shares held steady in after-hours trading. Insmed also announced the acquisition of INS1148, a Phase 2–ready monoclonal antibody.
20 December 2025
·
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next

Insmed shares rose 5% to $174.90 Friday after a steep Thursday drop, following news that its Phase 2b BiRCh trial in CRSsNP missed endpoints and the program was discontinued. Trading volume spiked Thursday as shares fell 16%. The rebound came as analysts reiterated Buy ratings, citing Insmed’s bronchiectasis franchise and respiratory pipeline. The stock remains below its 52-week high of $212.75.
19 December 2025
·
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed shares fell 16% Thursday after the company said its Phase 2b trial of brensocatib in chronic rhinosinusitis without nasal polyps failed to meet endpoints, prompting it to end development for that indication. The drug’s performance matched or trailed placebo on symptom scores. Insmed reported no new safety issues. The stock traded near $166.75 after hitting a low of $158.06.
18 December 2025
···

Stock Market Today

RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

RELX share price slides again on AI worries; what to watch ahead of Feb 12 results

8 February 2026
RELX shares fell 4.6% to 2,145p on Friday, near a 52-week low, despite the FTSE 100 closing higher. The company disclosed a new buyback of 465,361 shares on Feb. 6 and has repurchased over 8.8 million shares since Jan. 2. Investors await RELX’s full-year 2025 results on Feb. 12 amid concerns over AI’s impact on its core business.
Glencore shares steady after Rio walks away — what to watch before Monday’s trade

Glencore shares steady after Rio walks away — what to watch before Monday’s trade

8 February 2026
Glencore shares closed up 0.6% at 478.10 pence Friday after Rio Tinto ended merger talks, issuing a “no intention to bid” statement. Glencore’s board rejected the proposed deal terms, citing concerns over valuation and governance. Attention now turns to possible asset sales, including its $5 billion Kazzinc stake, ahead of Glencore’s annual results on Feb. 18.
Go toTop